Clinical Trial Supply Chain

As studies become more complex, stakeholders must be aware of the resources they are utilizing and their impact on the environment.

According to the session panelists, tackling challenges and finding efficiencies is imperative for success.

As clinical research continues to globalize and grow at pace, there is a risk that global greenhouse gas emissions will escalate unless mitigation strategies are actively included in corporate strategies.

Siloed systems can make it difficult to marry data to support timely and informed decision-making and optimize clinical trial operations.

Insights on leveraging outsourcing partners to gain expert, streamlined, and personalized support.

Its integration is opening up more opportunities for sustainable study practices.

Emerging technologies like digital twins offer supply chain efficiency solutions, allowing the industry to integrate sustainable practices while ensuring patient safety.

In an earlier article, we reviewed the randomization risks that could arise if an interactive response technology (IRT) system isn’t designed and/or implemented correctly. Here we address the consequences that trial sponsors could face if their IRT system isn’t adequately designed to handle the many and often complex drug allocation and trial supply aspects of their clinical trials.

It is unrealistic to include infinite adaptations in an IRT system, thus identifying the optimal level of adaptations requires examination of the study’s characteristics and planning phase considerations.

Identifying areas of burden and steps supply chain operators can take to alleviate them.

AI can also help reduce waste from 70% to 25%.

Panel at SCOPE discusses the possibilities of research in a post-COVID world.

Concept of flexibility acting as driving force behind industry’s swift response to COVID-19.

How smart packaging can aid clinical trial adherence.

COVID-19 provides unique opportunity for overhaul of logistics.

The success of the decentralized model hinges on coordination between stakeholders across the supply chain to ensure that date is secure, medication is delivered on time, and in proper condition.

Expectations for trial design will continue to change, and it’s critical that IRT vendors continue to listen to their customers and evolve their offerings accordingly.

The importance of examining this generation’s influence on the clinical trial value chain.

Automation will be key to improving efficiency and mitigating risk during the complex process of cell therapy production and delivery.

Gaps in the good manufacturing practice controls on medicines for clinical trials are targeted in new rules from the EU.

In this article, MedCision executive discusses cell therapies.

4G Clinical head of marketing, Amy Ripston interviews Catherine Hall, director of operational excellence, at Sunovion to discuss how IRT bridges the gap between clinical and supply, and how interactive response technologies (IRT) can be leveraged to enable innovative trial designs.

Issues of counterfeit drugs being introduced into a supply chain have been a concern in comparative clinical trials. Terry Walsh of GSK speaks about the addressing this issue and ensuring that comparator drug supplies are more readily available for comparative trials.